Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Breast Neoplasms: HELP
Articles from European Institute of Oncology
Based on 577 articles published since 2009
||||

These are the 577 published articles about Breast Neoplasms that originated from European Institute of Oncology during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. 2018

Wolff, Antonio C / Hammond, M Elizabeth Hale / Allison, Kimberly H / Harvey, Brittany E / Mangu, Pamela B / Bartlett, John M S / Bilous, Michael / Ellis, Ian O / Fitzgibbons, Patrick / Hanna, Wedad / Jenkins, Robert B / Press, Michael F / Spears, Patricia A / Vance, Gail H / Viale, Giuseppe / McShane, Lisa M / Dowsett, Mitchell. ·Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore · Lisa M. McShane, National Cancer Institute, Bethesda, MD · M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT · Kimberly H. Allison, Stanford University School of Medicine, Stanford · Patrick Fitzgibbons, St Jude Medical Center, Fullerton · Michael F. Press, University of Southern California, Los Angeles, CA · Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA · John M.S. Bartlett, Ontario Institute for Cancer Research · Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada · Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia · Ian O. Ellis, The University of Nottingham, Nottingham · Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom · Robert B. Jenkins, Mayo Clinic, Rochester, MN · Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC · Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN · and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy. ·J Clin Oncol · Pubmed #29846122.

ABSTRACT: Purpose To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in > 10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended work-up for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥ 2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 4.0 and < 6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results. Find additional information at www.asco.org/breast-cancer-guidelines .

2 Guideline Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. 2018

Wolff, Antonio C / Hammond, M Elizabeth Hale / Allison, Kimberly H / Harvey, Brittany E / Mangu, Pamela B / Bartlett, John M S / Bilous, Michael / Ellis, Ian O / Fitzgibbons, Patrick / Hanna, Wedad / Jenkins, Robert B / Press, Michael F / Spears, Patricia A / Vance, Gail H / Viale, Giuseppe / McShane, Lisa M / Dowsett, Mitchell. ·Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy. ·Arch Pathol Lab Med · Pubmed #29846104.

ABSTRACT: PURPOSE.—: To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. METHODS.—: Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. RECOMMENDATIONS.—: Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended workup for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥2.0; average HER2 copy number <4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio <2.0; average HER2 copy number ≥6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio <2.0; average HER2 copy number ≥4.0 and <6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results.

3 Guideline 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). 2017

Cardoso, F / Costa, A / Senkus, E / Aapro, M / André, F / Barrios, C H / Bergh, J / Bhattacharyya, G / Biganzoli, L / Cardoso, M J / Carey, L / Corneliussen-James, D / Curigliano, G / Dieras, V / El Saghir, N / Eniu, A / Fallowfield, L / Fenech, D / Francis, P / Gelmon, K / Gennari, A / Harbeck, N / Hudis, C / Kaufman, B / Krop, I / Mayer, M / Meijer, H / Mertz, S / Ohno, S / Pagani, O / Papadopoulos, E / Peccatori, F / Penault-Llorca, F / Piccart, M J / Pierga, J Y / Rugo, H / Shockney, L / Sledge, G / Swain, S / Thomssen, C / Tutt, A / Vorobiof, D / Xu, B / Norton, L / Winer, E. ·European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. · European School of Oncology, Milan, Italy and European School of Oncology, Bellinzona, Switzerland. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Breast Center, Genolier Cancer Center, Genolier, Switzerland. · Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France. · Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil. · Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden. · Department of Medical Oncology, Fortis Hospital, Kolkata, India. · Medical Oncology Department, Hospital of Prato, Prato, Italy. · Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. · Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center. · METAvivor Research and Support, Annapolis, USA. · Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy. · Department of Medical Oncology, Institut Curie, Paris, France. · NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon. · Department of Breast Tumors, Cancer Institute 'I. Chiricuta', Cluj-Napoca, Romania. · Brighton & Sussex Medical School, University of Sussex, Falmer, UK. · Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta. · Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. · BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada. · Department of Medical Oncology, Galliera Hospital, Genoa, Italy. · Brustzentrum der Universitat München, Munich, Germany. · Breast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA. · Sheba Medical Center, Tel Hashomer, Israel. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston. · Advanced Breast Cancer.org, New York, USA. · Department of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands. · Metastatic Breast Cancer Network US, Inversness, USA. · Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan. · Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland. · Europa Donna, Nicosia, Cyprus. · European School of Oncology, Milan, Italy and Bellinzona, Switzerland. · Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France. · Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. · Department of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France. · Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco. · Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore. · Indiana University Medical CTR, Indianapolis. · Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA. · Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany. · Breakthrough Breast Cancer Research Unit, King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UK. · Sandton Oncology Centre, Johannesburg, South Africa. · Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. · Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. ·Ann Oncol · Pubmed #28177437.

ABSTRACT: -- No abstract --

4 Guideline 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). 2017

Cardoso, F / Costa, A / Senkus, E / Aapro, M / André, F / Barrios, C H / Bergh, J / Bhattacharyya, G / Biganzoli, L / Cardoso, M J / Carey, L / Corneliussen-James, D / Curigliano, G / Dieras, V / El Saghir, N / Eniu, A / Fallowfield, L / Fenech, D / Francis, P / Gelmon, K / Gennari, A / Harbeck, N / Hudis, C / Kaufman, B / Krop, I / Mayer, M / Meijer, H / Mertz, S / Ohno, S / Pagani, O / Papadopoulos, E / Peccatori, F / Penault-Llorca, F / Piccart, M J / Pierga, J Y / Rugo, H / Shockney, L / Sledge, G / Swain, S / Thomssen, C / Tutt, A / Vorobiof, D / Xu, B / Norton, L / Winer, E. ·European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt. · European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Breast Center, Genolier Cancer Center, Genolier, Switzerland. · Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France. · Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil. · Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden. · Department of Medical Oncology, Fortis Hospital, Kolkata, India. · Medical Oncology Department, Hospital of Prato, Prato, Italy. · Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. · Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, USA. · METAvivor Research and Support, Annapolis, USA. · Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy. · Department of Medical Oncology, Institut Curie, Paris, France. · NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon. · Department of Breast Tumors, Cancer Institute 'I. Chiricuta', Cluj-Napoca, Romania. · Brighton & Sussex Medical School, University of Sussex, Falmer, UK. · Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta. · Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. · BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada. · Department of Medical Oncology, Galliera Hospital, Genoa, Italy. · Brustzentrum der Universitat München, Munich, Germany. · Breast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA. · Sheba Medical Center, Tel Hashomer, Israel. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. · Advanced BC.org, New York, USA. · Department of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands. · Metastatic Breast Cancer Network US, Inversness, USA. · Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan. · Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland. · Europa Donna, Nicosia, Cyprus. · Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France. · Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. · Department of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France. · Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. · Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore, USA. · Indiana University Medical CTR, Indianapolis, USA. · Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA. · Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany. · Breakthrough Breast Cancer Research Unit, King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UK. · Sandton Oncology Centre, Johannesburg, South Africa. · Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. · Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA. ·Breast · Pubmed #27927580.

ABSTRACT: -- No abstract --

5 Guideline Surgical resection margins after breast-conserving surgery: Senonetwork recommendations. 2016

Galimberti, Viviana / Taffurelli, Mario / Leonardi, Maria Cristina / Aristei, Cynthia / Trentin, Chiara / Cassano, Enrico / Pietribiasi, Francesca / Corso, Giovanni / Munzone, Elisabetta / Tondini, Carlo / Frigerio, Alfonso / Cataliotti, Luigi / Santini, Donatella. ·Molecular Senology Unit, European Institute of Oncology, Milan - Italy. · Department of Medical and Surgical Sciences, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna - Italy. · Radiation Oncology Division, European Institute of Oncology, Milan - Italy. · Radiation Oncology Section, University of Perugia and Santa Maria della Misericordia Hospital, Perugia - Italy. · Breast Imaging Division, European Institute of Oncology, Milan - Italy. · Pathology Unit, S. Croce Hospital, ASL TO 5, Moncalieri (Turin) - Italy. · Division of Medical Senology, European Institute of Oncology, Milan - Italy. · Unit of Medical Oncology, Department of Oncology and Hematology, Hospital Pope John XXIII, Bergamo - Italy. · Regional Reference Center for Breast Cancer Screening, Turin - Italy. · University of Florence, Senonetwork Italia, Florence - Italy. · Pathology Unit, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna - Italy. ·Tumori · Pubmed #27103209.

ABSTRACT: This paper reports findings of the "Focus on Controversial Areas" Working Party of the Italian Senonetwork, which was set up to improve the care of breast cancer patients. After reviewing articles in English on the MEDLINE system on breast conserving surgery for invasive carcinoma, the Working Party presents their recommendations for identifying risk factors for positive margins, suggests how to manage them so as to achieve the highest possible percentage of negative margins, and proposes standards for investigating resection margins and therapeutic approaches according to margin status. When margins are positive, approaches include re-excision, mastectomy, or, as second-line treatment, radiotherapy with a high boost dose. When margins are negative, boost administration and its dose depend on the risk of local recurrence, which is linked to biopathological tumor features and surgical margin width. Although margin status does not affect the choice of systemic therapy, it may delay the start of chemotherapy when further surgery is required.

6 Guideline Second international consensus guidelines for breast cancer in young women (BCY2). 2016

Paluch-Shimon, Shani / Pagani, Olivia / Partridge, Ann H / Bar-Meir, Eran / Fallowfield, Lesley / Fenlon, Deborah / Friedman, Eitan / Gelmon, Karen / Gentilini, Oreste / Geraghty, James / Harbeck, Nadia / Higgins, Stephen / Loibl, Sibylle / Moser, Elizabeth / Peccatori, Fedro / Raanani, Hila / Kaufman, Bella / Cardoso, Fatima. ·Sheba Medical Center, Ramat Gan, Israel. · Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Faculty of Medicine, Bar-Ilan University, Israel. · SHORE-C, Brighton & Sussex Medical School, University of Sussex, Falmer, UK. · University of Southampton, Southampton, UK. · British Columbia Cancer Agency, Vancouver, Canada. · Breast Surgery Unit, San Raffaele Hospital, Milan, Italy. · St Vincent Hospital, Dublin, Ireland. · Breast Center, Dept. OB&GYN, University of Munich (LMU), Munich, Germany. · Tallaght Hospital & Our Lady's Hospice, Dublin, Ireland. · German Breast Group, Neu-Isenburg, & Sana Klinikum Offenbach, Germany. · Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal. · European Institute of Oncology, Milan, Italy. · Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal; European School of Oncology, Italy. Electronic address: fatimacardoso@fundacaochampalimaud.pt. ·Breast · Pubmed #27017247.

ABSTRACT: The 2nd International Consensus Conference for Breast Cancer in Young Women (BCY2) took place in November 2014, in Dublin, Ireland organized by the European School of Oncology (ESO). Consensus recommendations for the management of breast cancer in young women (BCYW) were updated from BCY1 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified. This manuscript summarizes these international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA).

7 Guideline Optimal breast cancer pathology manifesto. 2015

Tot, T / Viale, G / Rutgers, E / Bergsten-Nordström, E / Costa, A / Anonymous5270839. ·Uppsala University and Head of Laboratory Medicine Dalarna at the County Hospital, Falun, Sweden. Electronic address: tibor.tot@ltdalarna.se. · Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy. · The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Europa Donna Patient Advocate, Sweden. · European School of Oncology, Milan, Italy. ·Eur J Cancer · Pubmed #26283037.

ABSTRACT: This manifesto was prepared by a European Breast Cancer (EBC) Council working group and launched at the European Breast Cancer Conference in Glasgow on 20 March 2014. It sets out optimal technical and organisational requirements for a breast cancer pathology service, in the light of concerns about variability and lack of patient-centred focus. It is not a guideline about how pathology services should be performed. It is a call for all in the cancer community--pathologists, oncologists, patient advocates, health administrators and policymakers--to check that services are available that serve the needs of patients in a high quality, timely way.

8 Guideline Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. 2015

Provenzano, Elena / Bossuyt, Veerle / Viale, Giuseppe / Cameron, David / Badve, Sunil / Denkert, Carsten / MacGrogan, Gaëtan / Penault-Llorca, Frédérique / Boughey, Judy / Curigliano, Giuseppe / Dixon, J Michael / Esserman, Laura / Fastner, Gerd / Kuehn, Thorsten / Peintinger, Florentia / von Minckwitz, Gunter / White, Julia / Yang, Wei / Symmans, W Fraser / Anonymous3320837. ·Department of Histopathology and NIH Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK. · Department of Pathology, Yale University, New Haven, CT, USA. · Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy. · Edinburgh Cancer Research UK Centre,University of Edinburgh, Edinburgh, UK. · Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. · Institute of Pathology, Charité Hospital, Berlin, Germany. · Department of Biopathology, Institut Bergonié, Bordeaux, France. · Department of Pathology, Centre Jean Perrin and Université d'Auvergne, Clermont-Ferrand, France. · Division of Subspecialty General Surgery, Mayo Clinic, Rochester, MN, USA. · Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy. · Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK. · Carol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA. · Department of Radiotherapy and Radiation Oncology, Landeskrankenhaus, Paracelsus Medical University, Salzburg, Austria. · Department of Gynecology and Obstetrics, Interdisciplinary Breast Center, Klinikum Esslingen, Esslingen, Germany. · Institute of Pathology, Medical University of Graz, Graz, Austria. · Department of Gynecology, General Hospital Leoben, Leoben, Austria. · German Breast Group, Neu-Isenburg, and Department of Gynecology and Obstetrics, University Women's Hospital, Frankfurt, Germany. · Department of Radiation Oncology, Ohio State University, Columbus, OH, USA. · Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ·Mod Pathol · Pubmed #26205180.

ABSTRACT: Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of survival after neoadjuvant therapy. Thus, pathological complete response has become a primary end point for clinical trials. However, there is a current lack of uniformity in the definition of pathological complete response. A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting. An international working group was convened to develop practical recommendations for the pathologic assessment of residual disease in neoadjuvant clinical trials of breast cancer and information expected from pathology reports. Systematic sampling of areas identified by informed mapping of the specimen and close correlation with radiological findings is preferable to overly exhaustive sampling, and permits taking tissue samples for translational research. Controversial areas are discussed, including measurement of lesion size, reporting of lymphovascular space invasion and the presence of isolated tumor cells in lymph nodes after neoadjuvant therapy, and retesting of markers after treatment. If there has been a pathological complete response, this must be clearly stated, and the presence/absence of residual ductal carcinoma in situ must be described. When there is residual invasive carcinoma, a comment must be made as to the presence/absence of chemotherapy effect in the breast and lymph nodes. The Residual Cancer Burden is the preferred method for quantifying residual disease in neoadjuvant clinical trials in breast cancer; other methods can be included per trial protocols and regional preference. Posttreatment tumor staging using the Tumor-Node-Metastasis system should be included. These recommendations for standardized pathological evaluation and reporting of neoadjuvant breast cancer specimens should improve prognostication for individual patients and allow comparison of treatment outcomes within and across clinical trials.

9 Guideline Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. 2015

Gourgou-Bourgade, S / Cameron, D / Poortmans, P / Asselain, B / Azria, D / Cardoso, F / A'Hern, R / Bliss, J / Bogaerts, J / Bonnefoi, H / Brain, E / Cardoso, M J / Chibaudel, B / Coleman, R / Cufer, T / Dal Lago, L / Dalenc, F / De Azambuja, E / Debled, M / Delaloge, S / Filleron, T / Gligorov, J / Gutowski, M / Jacot, W / Kirkove, C / MacGrogan, G / Michiels, S / Negreiros, I / Offersen, B V / Penault Llorca, F / Pruneri, G / Roche, H / Russell, N S / Schmitt, F / Servent, V / Thürlimann, B / Untch, M / van der Hage, J A / van Tienhoven, G / Wildiers, H / Yarnold, J / Bonnetain, F / Mathoulin-Pélissier, S / Bellera, C / Dabakuyo-Yonli, T S / Anonymous1750822. ·Biostatistic Unit, Montpellier Cancer Institute, Montpellier Data Center for Cancer Clinical Trials, CTD-INCa, Montpellier, France sophie.gourgou@icm.unicancer.fr. · Edinburgh Cancer Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK. · Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands. · Department of Biostatistics, Institut Curie, Paris. · Department of Radiation Oncology, Montpellier Cancer Institute, Montpellier, France. · Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal. · Institute of Cancer Research, London, UK. · EORTC Data Center (European Organization of Research and Treatment of Cancer - Statistics Department), Brussels, Belgium. · Institut Bergonié, Comprehensive Cancer Centre, Bordeaux. · Departments of Clinical Research and Medical Oncology, Institut Curie - Hôpital René Huguenin, Saint-Cloud. · Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France. · FRCP, FRCPE YCR National Institute for Health Research Cancer Research Network (NCRN), Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Cancer Research Centre, Sheffield, UK. · University Clinic Golnik, Golnik, Slovenia. · Institut Jules Bordet, University 'Libre' of Brussels, Brussels, Belgium. · Institut Claudius Régaud, Toulouse. · Breast Cancer Group, Gustave Roussy Institute, Villejuif. · APHP Tenon - University Cancer Institute - Pierre & Marie Curie, Sorbonne University, Paris. · Department of Surgery. · Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France. · Université catholique Louvain, Louvain-la-Neuve, Belgium. · Biostatistic and Epidemiology Unit, Gustave Roussy, Villejuif University of Paris-Sud, Villejuif, France. · Breast Unit, Hospital CUF Descobertas, Lisbon, Portugal. · Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. · Centre Jean Perrin, Clermont-Ferrand ERTICA EA4677, UFR Medicine, University of Clermont-Ferrand 1, Clermont-Ferrand, France. · European Institute of Oncology, Milan University of Milan, School of Medicine, Milan, Italy. · Department of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwnhoek Hospital, Amsterdam, The Netherlands. · IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Porto Medical Faculty of Porto University, Porto, Portugal. · Oscar Lambret Comprehensive Cancer Center, Lille, France. · Kantonsspital St Gallen, Breast Center, St Gallen, Switzerland. · Clinic for Gynecology, Gynecologic Oncology and Obstetrics-Interdisciplinary Breast Cancer Center, HELIOS Klinikum Berlin-Buch, Berlin, Germany. · Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam. · Academic Medical Center Amsterdam, Amsterdam, The Netherlands. · Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, Leuven, Belgium. · The Institute of Cancer Research, Royal Cancer Hospital, London, UK. · Methodological and Quality of Life Unit in Oncology (EA3181), CHU Besançon, Besançon. · Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux. · Biostatistics and Quality of Life Unit (EA4184), Centre Georges François Leclerc Comprehensive Cancer Centre, Dijon, France. ·Ann Oncol · Pubmed #25725046.

ABSTRACT: BACKGROUND: Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for randomized cancer clinical trials (RCTs) in breast cancer. PATIENTS AND METHODS: A literature review was carried out to identify TTE end points (primary or secondary) reported in publications of randomized trials or guidelines. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points based on a validated consensus method that formalize the degree of agreement among experts. RESULTS: Recommended guidelines for the definitions of TTE end points commonly used in RCTs for breast cancer are provided for non-metastatic and metastatic settings. CONCLUSION: The use of standardized definitions should facilitate comparisons of trial results and improve the quality of trial design and reporting. These guidelines could be of particular interest to those involved in the design, conducting, reporting, or assessment of RCT.

10 Guideline The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. 2015

Salgado, R / Denkert, C / Demaria, S / Sirtaine, N / Klauschen, F / Pruneri, G / Wienert, S / Van den Eynden, G / Baehner, F L / Penault-Llorca, F / Perez, E A / Thompson, E A / Symmans, W F / Richardson, A L / Brock, J / Criscitiello, C / Bailey, H / Ignatiadis, M / Floris, G / Sparano, J / Kos, Z / Nielsen, T / Rimm, D L / Allison, K H / Reis-Filho, J S / Loibl, S / Sotiriou, C / Viale, G / Badve, S / Adams, S / Willard-Gallo, K / Loi, S / Anonymous1800806. ·Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium. · Institute of Pathology, Charité -University Hospital, Berlin, Germany. · Perlmutter Cancer Center, New York University Medical School, New York, USA. · Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. · European Institute of Oncology (IEO) and University of Milan, Milan, Italy. · Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium. · Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA. · Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France. · Division of Haematology/Medical Oncology and. · Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville. · Department of Pathology, The UT M.D. Anderson Cancer Center, Boston. · Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston. · Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA. · Istituto Europeo di Oncologia, Milan, Italy. · Genomic Health, Inc., Redwood City, USA. · Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels. · Department of Pathology, University Hospital Leuven, Leuven, Belgium. · Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA. · Laboratory Medicine Program, University Health Network, University of Toronto, Toronto. · Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. · Department of Pathology, Yale University School of Medicine, New Haven. · Department of Pathology, Stanford University Medical Centre, Stanford. · Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA. · German Breast Group, Neu-Isenburg, Germany. · Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy. · Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA. · Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. · Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia sherene.loi@petermac.org. ·Ann Oncol · Pubmed #25214542.

ABSTRACT: BACKGROUND: The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN: A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS: The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.

11 Guideline ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 2014

Cardoso, F / Costa, A / Norton, L / Senkus, E / Aapro, M / André, F / Barrios, C H / Bergh, J / Biganzoli, L / Blackwell, K L / Cardoso, M J / Cufer, T / El Saghir, N / Fallowfield, L / Fenech, D / Francis, P / Gelmon, K / Giordano, S H / Gligorov, J / Goldhirsch, A / Harbeck, N / Houssami, N / Hudis, C / Kaufman, B / Krop, I / Kyriakides, S / Lin, U N / Mayer, M / Merjaver, S D / Nordström, E B / Pagani, O / Partridge, A / Penault-Llorca, F / Piccart, M J / Rugo, H / Sledge, G / Thomssen, C / Van't Veer, L / Vorobiof, D / Vrieling, C / West, N / Xu, B / Winer, E / Anonymous1680807 / Anonymous1690807. ·European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt. · European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland. · Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA. · Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland. · Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland. · Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France. · Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil. · Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden. · Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy. · Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA. · Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal. · University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia. · NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon. · Brighton & Sussex Medical School, University of Sussex, Falmer, UK. · Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta. · Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. · BC Cancer Agency, Vancouver, Canada. · Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA. · APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, Arome, Paris, France. · Program of Breast Health, European Institute of Oncology, Milan, Italy. · Brustzentrum der Universität München, Munich, DE, USA. · Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia. · Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA. · Sheba Medical Center, Tel Hashomer, Israel. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. · Europa Donna Cyprus, Nicosa, Cyprus. · Advanced BC.org, New York, USA. · University of Michigan Medical School and School of Public Health, Ann Arbor, USA. · Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden. · Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland. · Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA. · Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France. · Department of Medicine, Institut Jules Bordet, Brussels, Belgium. · Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. · Indiana University Medical CTR, Indianapolis, USA. · Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany. · Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. · Sandton Oncology Centre, Johannesburg, South Africa. · Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland. · Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK. · Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. ·Breast · Pubmed #25244983.

ABSTRACT: -- No abstract --

12 Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. 2014

Wolff, Antonio C / Hammond, M Elizabeth H / Hicks, David G / Dowsett, Mitch / McShane, Lisa M / Allison, Kimberly H / Allred, Donald C / Bartlett, John M S / Bilous, Michael / Fitzgibbons, Patrick / Hanna, Wedad / Jenkins, Robert B / Mangu, Pamela B / Paik, Soonmyung / Perez, Edith A / Press, Michael F / Spears, Patricia A / Vance, Gail H / Viale, Giuseppe / Hayes, Daniel F / Anonymous3410771 / Anonymous3420771. ·Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. ·Arch Pathol Lab Med · Pubmed #24099077.

ABSTRACT: PURPOSE: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. METHODS: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing. RESULTS: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations. RECOMMENDATIONS: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to >10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing.

13 Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. 2013

Wolff, Antonio C / Hammond, M Elizabeth H / Hicks, David G / Dowsett, Mitch / McShane, Lisa M / Allison, Kimberly H / Allred, Donald C / Bartlett, John M S / Bilous, Michael / Fitzgibbons, Patrick / Hanna, Wedad / Jenkins, Robert B / Mangu, Pamela B / Paik, Soonmyung / Perez, Edith A / Press, Michael F / Spears, Patricia A / Vance, Gail H / Viale, Giuseppe / Hayes, Daniel F / Anonymous3750771 / Anonymous3760771. ·Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore · Lisa M. McShane, National Cancer Institute, Bethesda, MD · M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT · David G. Hicks, University of Rochester Medical Center, Rochester, NY · Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom · Kimberly H. Allison, Stanford University Medical Center, Stanford · Patrick Fitzgibbons, St Jude Medical Center, Fullerton · Michael F. Press, University of Southern California, Los Angeles, CA · Donald C. Allred, Washington University School of Medicine, St Louis, MO · John M.S. Bartlett, Ontario Institute for Cancer Research · Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada · Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia · Robert B. Jenkins, Mayo Clinic, Rochester, MN · Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA · Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA · Edith A. Perez, Mayo Clinic, Jacksonville, FL · Patricia A. Spears, North Carolina State University, Raleigh, NC · Gail H. Vance, Indiana University Medical Center, Indianapolis, IN · Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy · and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI. ·J Clin Oncol · Pubmed #24101045.

ABSTRACT: PURPOSE: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. METHODS: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing. RESULTS: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations. RECOMMENDATIONS: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to > 10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the College of American Pathologists and has been published jointly by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.

14 Guideline Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2013

Peccatori, F A / Azim, H A / Orecchia, R / Hoekstra, H J / Pavlidis, N / Kesic, V / Pentheroudakis, G / Anonymous4950762. ·Fertility and Procreation Unit, Division of Gynaecologic Oncology, European Institute of Oncology, Milan, Italy. ·Ann Oncol · Pubmed #23813932.

ABSTRACT: -- No abstract --

15 Editorial E-cadherin germline mutations in Māori population. 2019

De Scalzi, Alessandra Margherita / Bonanni, Bernardo / Galimberti, Viviana / Veronesi, Paolo / Pravettoni, Gabriella / Corso, Giovanni. ·Division of Breast Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy. · Division of Cancer Prevention & Genetics, European Institute of Oncology IRCCS, 20141 Milan, Italy. · Faculty of Medicine, University of Milan, Italy. · Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, 20141 Milan, Italy. ·Future Oncol · Pubmed #30977389.

ABSTRACT: -- No abstract --

16 Editorial Sentinel lymph node biopsy management after neoadjuvant treatment for breast cancer care. 2018

Corso, Giovanni / De Scalzi, Alessandra Margherita / Vicini, Elisa / Morigi, Consuelo / Veronesi, Paolo / Galimberti, Viviana. ·Division of Breast Cancer Surgery, European Institute of Oncology, via G. Ripamonti 435, 20141 Milano, Italy. · Faculty of Medicine, University of Milan, Milano, Italy. ·Future Oncol · Pubmed #29714081.

ABSTRACT: -- No abstract --

17 Editorial Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe! 2017

Curigliano, Giuseppe / Cardoso, Fatima. ·European Institute of Oncology, Via Giuseppe Ripamonti 435, 20141, Milano, Italy. Electronic address: giuseppe.curigliano@ieo.it. · Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. ·Breast · Pubmed #28734762.

ABSTRACT: -- No abstract --

18 Editorial PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer. 2017

Corso, Giovanni / Veronesi, Paolo / Intra, Mattia / Sacchini, Virgilio / Galimberti, Viviana. ·Breast Surgery Division, European Institute of Oncology, Milan, Italy. · School of Medicine, University of Milan, Milan, Italy. · Breast Day Surgery Unit, European Institute of Oncology, Milan, Italy. · Molecular Senology Unit, European Institute of Oncology, Milan, Italy. ·Biomark Med · Pubmed #28700273.

ABSTRACT: -- No abstract --

19 Editorial Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. 2017

Curigliano, G / Goldhirsch, A. ·Giuseppe Curigliano and Carmen Criscitiello, Istituto Europeo di Oncologia, Milano, Italy. · European Institute of Oncology, Milan, Italy. ·Ann Oncol · Pubmed #28426119.

ABSTRACT: -- No abstract --

20 Editorial From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. 2017

Curigliano, Giuseppe / Cardoso, Fatima / Costa, Alberto / Galimberti, Viviana / Goldhirsch, Aron / Pelicci, Pier Giuseppe / Veronesi, Paolo / Viale, Giuseppe / Orecchia, Roberto. ·European Institute of Oncology, Milano, Italy. Electronic address: giuseppe.curigliano@ieo.it. · Champalimaud Clinical Center, Lisbon, Portugal. · European School of Oncology, Milano, Italy. · European Institute of Oncology, Milano, Italy; University of Milan, Milano, Italy. · European Institute of Oncology, Milano, Italy. ·Breast · Pubmed #27876474.

ABSTRACT: -- No abstract --

21 Editorial Being more precise in assessing the value of precision medicine in breast cancer. 2016

Curigliano, Giuseppe. ·Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy. Electronic address: Giuseppe.curigliano@ieo.it. ·Breast · Pubmed #27600532.

ABSTRACT: -- No abstract --

22 Editorial Managing pregnancy-associated breast cancer: Is more really better? 2016

Peccatori, Fedro A / Azim, Hatem A. ·European Institute of Oncology, Via Ripamonti, 435-20141 Milan, Italy. Electronic address: fedro.peccatori@ieo.it. · Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium. ·Breast · Pubmed #27371969.

ABSTRACT: -- No abstract --

23 Editorial De-escalation attempts for adjuvant trastuzumab: longer beats shorter. 2015

Curigliano, G / Goldhirsch, A. ·Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy Program of Breast Health (Senology), European Institute of Oncology, Milan, Italy giuseppe.curigliano@ieo.it. · Program of Breast Health (Senology), European Institute of Oncology, Milan, Italy. ·Ann Oncol · Pubmed #26002609.

ABSTRACT: -- No abstract --

24 Editorial 'Tu quoque Brute fili mihi!' (Julius Caesar, Ides of March, 44 BC): role of tumor microenvironment and immune system in breast cancer progression. 2014

Curigliano, Giuseppe. ·Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milan, Italy. ·Curr Opin Oncol · Pubmed #25279960.

ABSTRACT: -- No abstract --

25 Editorial Immunoscoring breast cancer: TILs remember what they target. 2014

Curigliano, G / Perez, E A. ·Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy giuseppe.curigliano@ieo.it. · Division of Hematology/Medical Oncology and Cancer Biology, Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, FL, USA. ·Ann Oncol · Pubmed #24950980.

ABSTRACT: -- No abstract --

Next